Autor: |
Mezalek ZT; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Khibri H; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Ammouri W; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Bouaouad M; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco., Haidour S; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco., Harmouche H; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Maamar M; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Adnaoui M; Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.; Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco. |
Abstrakt: |
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions. |